Table 1.
Proportion of women in positions of leadership in clinical trials between 1 January 2020 and 26 June 2020 and before 1 January 2020
| 1 January 2020 to 26 June 2020 |
Before 1 January 2020 |
|||||||
|---|---|---|---|---|---|---|---|---|
| Coronavirus disease 2019 | Breast cancer | p value | Type 2 diabetes mellitus | p value | Breast cancer | Type 2 diabetes mellitus | p value | |
| Principal investigator | 27.8% (430/1548) | 54.9% (156/284) | <0.01 | 42.1% (56/133) | <0.01 | 49.7% (245/493) | 44.4% (148/333) | 0.15 |
| Study director | 28.7% (72/251) | 48.9% (23/47) | <0.01 | 22.2% (4/18) | 0.75 | 30.5% (29/95) | 47.6% (40/84) | 0.02 |
| Study chair | 31.4% (76/242) | 32.1% (9/28) | 1 | 63.6% (7/11) | 0.98 | 33.3% (26/78) | 40.4% (19/47) | 0.54 |